Business Context and Reporting Period
This Form 8-K reports the Initial Public Offering (IPO) of First Light Acquisition Group, Inc., a Special Purpose Acquisition Company (SPAC). The report date is September 9, 2021, with the IPO consummated on September 14, 2021. Note: The metadata provided lists "Calidi Biotherapeutics, Inc.", but the filing text explicitly identifies the registrant as First Light Acquisition Group, Inc.
Key Financial Metrics
- Gross Proceeds from IPO: $230,000,000 from the sale of 23,000,000 Units at $10.00 per Unit.
- Private Placement Proceeds: Approximately $5,095,733 from the sale of 3,397,155 Private Placement Warrants at $1.50 per warrant.
- Total Trust Account Funding: $230,000,000 (comprised of IPO proceeds and Private Placement Warrant proceeds).
- Warrant Exercise Price: $11.50 per share for both public and private warrants.
- Revenue/Profit/Cash Flow: The filing text does not provide operating revenue, net profit, or operating cash flow figures as the company is a pre-business combination SPAC.
Material Changes
This filing represents the company's initial entry into the public markets. There is no prior comparable period for financial performance as the entity was formed specifically for this IPO. The primary material change is the transition from a private entity to a public company with $230 million held in a trust account pending a business combination.
Outlook, Risks, and Contingencies
- Business Combination Timeline: The company must consummate an initial business combination within 12 months of the IPO closing, extendable by up to 18 months via two three-month extensions.
- Redemption Rights: Public shareholders have the right to redeem their shares for a pro-rata portion of the trust account if the company fails to complete a business combination within the specified timeframe or in connection with certain amendments to the charter.
- Trust Account Restrictions: Funds in the trust account are generally not accessible until the consummation of a business combination, except for interest earnings used to pay taxes.
- Private Placement Warrants: These warrants are non-redeemable while held by the Sponsor or Metric, non-transferable until 30 days after a business combination, and exercisable on a cashless basis.
Investor Verification Checklist
- Verify the identity of the registrant (First Light Acquisition Group, Inc.) versus the metadata label (Calidi Biotherapeutics, Inc.).
- Confirm the exact closing date of the IPO (September 14, 2021) and the deadline for the initial business combination.
- Review the terms of the over-allotment option (fully exercised for 3,000,000 Units).
- Examine the specific redemption scenarios and extension rights detailed in the Amended and Restated Certificate of Incorporation.
- Identify the Sponsor (First Light Acquisition Group, LLC) and Metric Finance Holdings I, LLC as holders of Private Placement Warrants.